Sarepta Therapeutics, Inc. (SRPT) Shares Gap Down on Analyst Downgrade

Several brokerages have issued reports on SRPT.

For the year, the company reported that its loss widened to $267.3 million, or $5.49 per share. Robert W. Baird reiterated an "outperform" rating and set a $102.00 price target on shares of Sarepta Therapeutics in a research note on Friday, November 4th. Royal Bank of Canada raised their target price on Sarepta Therapeutics from $98.00 to $106.00 and gave the stock an "outperform" rating in a research note on Friday, December 16th. They now have a Dollars 40 price target on the stock.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on February 28, 2017 granted equity awards, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2014 Employment Commencement Incentive Plan, as a material inducement to employment to four individuals hired by Sarepta in February 2017.

There are 1 sell rating, 3 hold ratings, 16 buy ratings, 1 strong buy rating on the stock.

Investors are on alert as Sarepta Therapeutics, Inc.

The stock's 50 day moving average is 31.11 and its 200 day moving average is 36.48. Company's distance from 20 day simple moving average is 6.16% and distance from 50-Day simple moving average is 1.96%.

Sarepta Therapeutics, Inc is a biopharmaceutical company. (SRPT) on Tuesday reported a loss of $88.5 million in its fourth quarter.

Struggling to find a way in profitable zone, the current EPS estimate trend for the next year first quarter was $-0.93 while three months ago that trend was for $-0.94.

On the sales side, SRPT's revenues are expected to climb to $1.25M versus prior year's Q4 result of $1.25M. The firm's revenue for the quarter was up 333.6% compared to the same quarter past year. Equities research analysts anticipate that Sarepta Therapeutics will post ($5.16) earnings per share for the current year.

"Sarepta Therapeutics, Inc. (SRPT) PT Lowered to $27.00" was originally published by BBNS and is the property of of BBNS. If you are reading this piece on another site, it was stolen and reposted in violation of United States & global copyright and trademark legislation.

Today, Sarepta Therapeutics (NASDAQ:SRPT) stock received an upgrade by Leerink Swann from Market Perform to Outperform.

For the full year 2016, the Cambridge, Massachusetts-based company reported a loss of $267.3 million, or $5.49 per share, compared to the previous year's loss of $220.03 million, or $5.20 per share. Cowen Prime Services LLC raised its position in Sarepta Therapeutics by 60.0% in the third quarter.

A number of institutional investors have recently bought and sold shares of the stock. Moody Aldrich Partners LLC bought a new position in Sarepta Therapeutics during the third quarter worth $1,233,000. BlackRock Advisors LLC now owns 839,928 shares of the company's stock worth $51,580,000 after buying an additional 697,122 shares during the period. Stifel Financial Corp increased its position in Sarepta Therapeutics by 5.4% in the second quarter. Rhumbline Advisers now owns 47,674 shares of the company's stock valued at $2,928,000 after buying an additional 955 shares during the period.

12/20/2016 - Goldman Sachs began new coverage on Sarepta Therapeutics, Inc. giving the company a " rating. The company's last traded volume of 3.4 million shares as compared to it's an average volume of 2.46 million shares.

In other Sarepta Therapeutics news, insider Sandesh Mahatme sold 30,000 shares of Sarepta Therapeutics stock in a transaction dated Monday, October 17th. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.

  • Joanne Flowers